CURIS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.46 USD | -1.31% |
|
-2.90% | +23.37% |
| May. 07 | Curis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| May. 07 | Transcript : Curis, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Presenter SpeechJason Russell (Analysts)And thanks for joining. My name is Jason Russell with ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Curis, Inc. is a biotechnology company. The Company is focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase (IRAK4). Emavusertib is undergoing testing in the Phase I/II TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase I/II TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS). Its other clinical programs include Fimepinostat and CA-170. Fimepinostat is an oral, dual inhibitor of histone deacetylase (HDAC), and phosphotidyl-inositol 3 kinase (PI3K) enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target V-domain Ig Suppressor of T-cell Activation (VISTA) and PDL1 immune checkpoint proteins.
Calendar
04:30pm
- Business Update Call
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
15.66
USD
Average target price
79.8
USD
Spread / Average Target
+409.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +23.37% | 92.3M | |
| +29.65% | 48.16B | |
| -1.01% | 41.73B | |
| +43.34% | 41.03B | |
| -5.31% | 28.77B | |
| +10.22% | 25.59B | |
| -21.21% | 18.96B | |
| +6.70% | 12.92B | |
| +26.92% | 12.03B | |
| -3.10% | 11.77B |
- Stock Market
- Equities
- CRIS Stock
- News Curis, Inc.
- Transcript : Curis, Inc. Presents at Morgan Stanley 19th Annual Global Healthcare Conference, Sep-10-2021 11